Authors

• Marla C. Dubinsky (ORCID: https://orcid.org/0000-0003-4968-5795)
• Marc Fellmann (ORCID: https://orcid.org/0000-0003-0064-698X)
• Martina Goetsch
• Julián Panés (ORCID: https://orcid.org/0000-0002-4971-6902)
• María Chaparro (ORCID: https://orcid.org/0000-0002-9275-4242)
• Alessandro Armuzzi (ORCID: https://orcid.org/0000-0003-1572-0118)
• Lauren Bartolome (ORCID: https://orcid.org/0000-0002-0649-2902)
• David Gruben (ORCID: https://orcid.org/0000-0003-3516-5289)
• Abhishek Bhattacharjee (ORCID: https://orcid.org/0000-0002-2585-2993)
• David T. Rubin (ORCID: https://orcid.org/0000-0001-5647-1723)
• S Schreiber

Institutions

• Humanitas University (IT)
• Pfizer (United States) (US)
• Christian-Albrechts-Universität zu Kiel (DE)
• University of Chicago (US)
• Pfizer (Switzerland) (CH)
• University Hospital Schleswig-Holstein (DE)
• Centro de Investigación Biomédica en Red (ES)
• Hospital Clínic de Barcelona (ES)
• Hospital Universitario de La Princesa (ES)
• Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
• IRCCS Humanitas Research Hospital (IT)
• Pfizer (India) (IN)
• Universidad Autónoma de Madrid (ES)
• University of Lübeck (DE)
• Icahn School of Medicine at Mount Sinai (US)

Publication Details

Journal

Inflammatory Bowel Diseases

Published

2024-09-26

DOI

https://doi.org/10.1093/ibd/izae229

Citations

2

Primary Topic

Inflammatory Bowel Disease

Type

article

Field-Weighted Citation Impact

1.10

Funders

• Amgen
• Bristol-Myers Squibb
• Eli Lilly and Company
• Pfizer
• Gilead Sciences
• Biogen
• Celgene
• Leona M. and Harry B. Helmsley Charitable Trust
• Mylan
• Celltrion
• Tillotts Pharma
• Samsung
• Janssen Pharmaceuticals